Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 25 Sep 2026
₹196.64
Change
+4.1 (2.13%)
Open
₹187.0
Prev. Close
₹192.54
Day High
₹199.9
Day Low
₹186.9
Volume Analysis
Traded
82,555
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Trading within 3% of its 52-week high (₹200.0)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹215.06 | ₹207.48 | ₹202.06 | ₹194.48 | ₹189.06 | ₹181.48 | ₹176.06 |
| Fibonacci | ₹207.48 | ₹202.51 | ₹199.45 | ₹194.48 | ₹189.51 | ₹186.45 | ₹181.48 |
| Camarilla | ₹200.22 | ₹199.02 | ₹197.83 | ₹194.48 | ₹195.45 | ₹194.26 | ₹193.07 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+5.6%
1 Month
+29.46%
3 Months
+92.97%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹79.72
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.79%
Net margin 7.1% × asset turnover 0.81x × equity multiplier 2.05x
Company Overview
Sector
Healthcare
Market Cap
₹380 Cr
P/E (TTM)
35.4
ROE
10.4%
Book Value
₹53.9
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Qms Medical Allied S Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 56/100. The strongest factor is Momentum (98/100), while Liquidity (6/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹200.0); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
56/100 — AverageData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 56.4%
- −Stock is trading at 3.65 times its book value
- −Company has a low return on equity of 12.0% over last 3 years.
- −Promoter holding has decreased over last 3 years: -5.56%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
QMS and HCAH signed definitive documents to merge PSP businesses into Saarathi, targeting 160+ programs.
25 Sept 2026 board approved composite scheme demerging healthcare services business into Saarathi and BeamOptics acquisition.
Board approved healthcare demerger, merger agreements, and 100% acquisition of BeamOptics Scientific on 25 September 2026.
Board approved composite scheme demerging healthcare services into Saarathi and acquisition of BeamOptics Scientific on 25 Sep 2026.
Board approved healthcare services demerger into Saarathi and acquisition of 100% BeamOptics on 25 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 35 | 32 | 37 | 44 | 45 | 47 | 45 | 37 | 44 | 57 |
| Expenses + | 30 | 28 | 30 | 37 | 38 | 40 | 38 | 31 | 39 | 49 |
| Operating Profit | 5 | 4 | 7 | 7 | 6 | 7 | 7 | 7 | 6 | 8 |
| OPM % | 13.73% | 12.23% | 19.46% | 15.82% | 14.29% | 14.06% | 15.48% | 18.12% | 13.33% | 14.61% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 2 | 6 | 5 | 5 | 4 | 5 | 4 | 3 | 6 |
| Tax % | 25.76% | 29.68% | 25.27% | 30.24% | 23.24% | 29.62% | 26.24% | 25.7% | 29.21% | 28.65% |
| Net Profit + | 2 | 2 | 4 | 3 | 4 | 3 | 4 | 3 | 2 | 4 |
| EPS in Rs | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales + | 122 | 156 | 173 | 183 |
| Expenses + | 104 | 130 | 147 | 155 |
| Operating Profit | 18 | 25 | 26 | 28 |
| OPM % | 15.0% | 16.0% | 15.0% | 15.0% |
| Other Income + | 0 | 2 | 1 | 1 |
| Interest | 3 | 5 | 7 | 7 |
| Depreciation | 3 | 4 | 4 | 5 |
| Profit before tax | 12 | 19 | 16 | 17 |
| Tax % | 26.0% | 27.0% | 27.0% | — |
| Net Profit + | 9 | 14 | 12 | 13 |
| EPS in Rs | 5 | 6 | 5 | 6 |
| Dividend Payout % | 0.0% | 74.0% | 95.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Reserves | 61 | 72 | 85 |
| Borrowings + | 35 | 60 | 74 |
| Other Liabilities + | 22 | 40 | 34 |
| Total Liabilities | 135 | 190 | 213 |
| Fixed Assets + | 24 | 52 | 55 |
| CWIP | 2 | 3 | 3 |
| Investments | 2 | 3 | 5 |
| Other Assets + | 108 | 131 | 150 |
| Total Assets | 135 | 190 | 213 |
| Equity Capital | 18 | 18 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from Operating Activity + | 1 | 19 | 19 |
| Cash from Investing Activity + | -3 | -45 | -20 |
| Cash from Financing Activity + | 0 | 27 | 1 |
| Net Cash Flow | -1 | 1 | 0 |
| CFO/OP | 26 | 97 | 93 |
| Free Cash Flow | 1 | 19 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Public | 25.62% | 25.12% | 25.32% | 26.33% | 26.33% | 26.33% | 26.33% | 30.28% | 30.3% | 30.3% |
| Promoters | 73.67% | 73.67% | 73.67% | 73.67% | 73.67% | 73.67% | 73.67% | 68.11% | 68.11% | 68.11% |
| FII | 0.71% | 1.21% | 1.02% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.6% | 1.59% | 1.59% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Qms Medical Allied S Ltd (this stock) | 380 | 35.4 | 3.65 | 10.4% |
| Nureca Limited | 335 | 77.3 | 1.86 | 1.12% |
| Medicamen Biotech Limited | 428 | 39.4 | 1.55 | 3.95% |
| Haleos Labs Limited | 444 | 28.1 | 2.08 | 8.44% |
| Ambalal Sarabhai Ent L | 316 | 22.2 | 2.0 | 12.4% |
| Lyka Labs Ltd. | 310 | — | 3.31 | -10.2% |
| Rays Of Belief Limited | 466 | 93.9 | — | 16.1% |
Which Mutual Funds Hold Qms Medical Allied S Ltd?
Frequently Asked Questions about Qms Medical Allied S Ltd
Qms Medical Allied S Ltd (QMSMEDI) closed at ₹196.64 on NSE on 25 September 2026, up 4.1 (2.13%) from the previous close.
Qms Medical Allied S Ltd trades on the NSE (National Stock Exchange of India) under the symbol QMSMEDI.
Qms Medical Allied S Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 35.4.
Qms Medical Allied S Ltd has a dividend yield of 0.25%.
Qms Medical Allied S Ltd's 52-week high is ₹200.0 and its 52-week low is ₹69.0.
Qms Medical Allied S Ltd has a market capitalisation of ₹380 crore.
Qms Medical Allied S Ltd has a TopFund Quality Score of 56/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Qms Medical Allied S Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.